01). The number of Pulmonary metastasis tubercle and AFP after As2O3 effect were obviously lower than those of controls group (P < 0.01). The As2O3 groups could depress expression of MIF, IL-8,

bFGF and HIF-1α (P < 0.05). Conclusion: As2O3 can inhibit invasion and metastasis of hepatoma, further inhibit the expression of MIF, IL-8, bFGF BTK inhibitor and HIF-1α. Key Word(s): 1. As2O3; 2. hepatoma; 3. MIF; 4. IL-8; Presenting Author: ADHOUTE XAVIER Additional Authors: CASTELLANI PAUL, PERRIER HERVÉ, CAMPANILE MANUELA, POL BERNARD, MONNET OLIVIER, BAYLE OLIVIER, LEFOLGOC GAELLE, PENARANDA GUILLAUME, BOURLIÈRE MARC, RAOUL JEAN LUC Corresponding Author: ADHOUTE XAVIER Affiliations: Fondation Saint-joseph; Alphabio Laboratory; Institut Paoli Calmettes Objective: Introduction: TACE is recommended for intermediate stage HCC BCLC B, which includes a wide spectrum of tumors. TACE may also be a treatment option for inoperable limited HCC. Selection of patients is necessary. The score ART selects which patients with unresectable HCC should receive a second TACE. It is calculated before the second TACE and based on elevated transaminases, increased Child-Pugh score and the absence of radiological response. Defined from a cohort of 107 patients with predominantly alcoholic cirrhosis, there are two different prognostic groups (0–1.5 click here points and ≥2.5 points) with respective survival

23.7 vs 6.6 months (p < 0.001.(Sieghart W and al Hepatology. 2013 Jan 12). Aim of study: to assess the prognostic

value of ART score in a French cohort of HCC developed mostly on viral cirrhosis (HCV and HBV). Methods: During the period 01/2007 – 12/2012, 373 consecutive patients were admitted to our unit for the management of HCC. 52% of patients (n = 195) were treated with TACE. In this group, 73 pts have a limited CHC. Were excluded from the analysis: TACE before a graft and patients who received additional check details treatment after TACE. The population used for the analysis included 139 patients. This population include mostly men (84%), mean age 67 years. Cirrhosis was present in 96% of cases. Esophageal varices grade 2 or 3 were present in 37% of pts. Underlying liver disease was viral (HCV 38%, HBV 6%, HIV coinfection 3%), mixed in 5% (HCV, alcohol), alcohol-related (35%), a steatopathy (10%) or related to another etiology in 3% of cases. Type 2 diabetes was present in 32% of pts. The median BMI was 25. 70% of HCC were diagnosed during a screening, 13% of HCC were revealed by symptoms and 17% incidental discovery. 15% of pts had a history of HCC treated by RF or surgery. 46% of pts were in the Milan criteria, 23% of pts had a single nodule. These patients for medical reasons could not get a graft. 46% of HCC were BCLC A, 31% BCLC B, 19% BCLC C. Segmental portal vein thrombosis was present in 14% of HCC, 17% were infiltrating tumors. The median AFP level was 23 ng.ml. Pts were treated on average by two TACE.